Atlantic Equities: Time To Buy Johnson & Johnson (NYSE:JNJ)? Has $95.00 Valuation Target

Share

Why Has Atlantic Equities Given Johnson & Johnson (NYSE:JNJ) a $95.00 Price Target

Research professionals at Atlantic Equities a key Neutral rating for Johnson & Johnson (NYSE:JNJ). The firm launched coverage in a note issued to investors and clients on 18 December. The TP may imply downside of -7.53% from the closing share price.

From a total of 15 analysts covering Johnson & Johnson (NYSE:JNJ) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $119 while the lowest target price is $95. The mean of all analyst targets is $108.87 with a 7.94% above today’s ($101.98) stock price. Johnson & Johnson was the topic of 14 analyst reports since August 7, 2015 according to the firm StockzIntelligence Inc. Barclays Capital upgraded shares on December 1 to “Overweight” rating. Vetr downgraded shares to “Strong-Buy” rating and $106.73 target share price in a report from an August 31. RBC Capital Markets maintained JNJ stock in a recent report from October 7 with “Outperform” rating. Cowen & Co maintained the rating on August 25. Cowen & Co has a “Outperform” rating and a $114 price target on shares. Finally, Deutsche Bank upgraded the stock to “Buy” rating in a report issued on a September 29.

Approximately 13.87M shares of stock traded hands or 92.37% up from the average. Johnson & Johnson (NYSE:JNJ) has risen 1.31% since May 15, 2015 and is uptrending. It has outperformed by 5.12% the S&P500.

The overall sentiment of institutions has increased to 1.22 in Q2 2015. Its up 0.26, from 0.96 in 2015Q2. The ratio improved, as 67 institutions have sold all the shares of Johnson & Johnson that they owned while 732 funds have taken shares off the table. 85 funds have purchased shares for the first time while 888 added to their positions. These institutions now hold 1.79 billion shares or 0.52% more than the 1.78 billion shares they owned in 2015Q2.

The Fund Robert Wood Johnson Foundation currently is holding shares equating to 99.86% of its total portfolio in Johnson & Johnson representing a total of 13.00 million shares. Another fund,Pettee Investors Inc., is holding a total of 159,596 shares equating to 15.59% of their holdings. Additionally, Cincinnati Indemnity Co has a 25,000 share stake in Johnson & Johnson which represents 11.49% of their total portfolio. The Fund, Tweedy Browne Co Llc, based out of Connecticut, has also built up a stake in the stock, which represents a total of 10.72% of their total portfolio. Finally Sector Gamma As, a fund which is based in the state of Norway reported a total holdings of 420,100 shares.

Insider activity is a very important aspect to track on any stock. Going back to March 9, 2015, shareholders of Johnson & Johnson have witnessed 0 buys, and a total of 1 insider sale equating to a net activity of approximately $621,904 . Kapusta Ronald A sold 6,239 shares worth approximately $621,904. Stoffels Paulus sold 187,250 shares worth approximately $18.86M. Fasolo Peter sold 115,307 shares worth approximately $11.81 million.

Johnson & Johnson is a holding company. The company has a market cap of $286.82 billion. The Firm is engaged in the research and development, manufacture and sale of a range of products in the health care field. It has 19.54 P/E ratio. The Firm has more than 265 operating companies conducting business around the world.

According to Zacks Investment Research, “Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women’s health fields, nutritional and over-the-counter pharmaceutical products. The company’s Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women’s health products. Johnson & Johnson is based in New Brunswick, New Jersey.”

COMMENTS: